Funding for this research was provided by:
Beatrice and Samuel A. Seaver Foundation
National Institute of Mental Health (R34 MH100276-01, R21 MH107839)
National Institute of Neurological Disorders and Stroke (K08 NS091381, U54 NS092090-01)
Phelan-McDermid Syndrome Foundation
Received: 1 February 2018
Accepted: 13 March 2018
First Online: 27 April 2018
Ethics approval and consent to participate
: The institutional review boards of the Icahn School of Medicine at Mount Sinai and Baylor College of Medicine approved this study. Participants were enrolled after written informed consent was obtained from parents or legal guardians.
: Written informed consent for publication was obtained from the parents or legal guardians.
: JDB and Mount Sinai hold a shared parent for the use of insulin-like growth factor-1 (IGF-1) in Phelan-McDermid syndrome. JDB is on the scientific advisory board for Coronis Neuroscience and has consulted for the Gerson Lehrman Group. AK is on the advisory board of Vencerx Therapeutics and consults for Ovid Therapeutics. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.